Drugs / TD-1058
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04589260 | Oct 2020 → May 2021 | idiopathic pulmonary fibrosis | Theravance Biopharma | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TD-1058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04589260 ↗ |
| Route | Inhaled | “Study drug to be administered by oral inhalation” NCT04589260 ↗ |